Ali Hassan Shilleh

Dr. Ali Hassan Shilleh

OCDEM, University of Oxford, Oxford, Oxfordshire, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SRStephan A. Ramos
Stephan A. Ramos
JMJohn J. Morton
John J. Morton
PYPrabha Yadav
Prabha Yadav
BRBrendan Reed
Brendan Reed
SASheila I. Alizadeh
Sheila I. Alizadeh
Holger Andreas RussHolger Andreas Russ
Holger Andreas Russ

22 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
ASAli Hassan Shilleh
Ali Hassan Shilleh
Holger Andreas RussHolger Andreas Russ
Holger Andreas Russ
Cell replacement therapy using stem-cell-derived insulin-producing β-like cells (sBCs) has been proposed as a practical cure for patients with type one diabetes (T1D). sBCs can correct diabetes in preclinical animal models, demonstrating the promise of this stem cell-based approach. However, in vivo studies have demonstrated that most sBCs, similarly to cadaveric human islets, are lost upon transplantation due to ischemia and other unknown mechanisms. Hence, there is a critical knowledge gap in the current field concerning the fate of sBCs upon engraftment. Here we review, discuss effects, and propose additional potential mechanisms that could contribute toward β-cell loss in vivo. We summarize and highlight some of the literature on phenotypic loss in β-cells under both steady, stressed, and diseased diabetic conditions. Specifically, we focus on β-cell death, dedifferentiation into progenitors, trans-differentiation into other hormone-expressing cells, and/or interconversion into less functional β-cell subtypes as potential mechanisms. While current cell replacement therapy efforts employing sBCs carry great promise as an abundant cell source, addressing the somewhat neglected aspect of β-cell loss in vivo will further accelerate sBC transplantation as a promising therapeutic modality that could significantly enhance the life quality of T1D patients.

30 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
TTTaylor M Triolo
Taylor M Triolo
JMJ. Quinn Matuschek
J. Quinn Matuschek
RCRoberto Castro-Gutierrez
Roberto Castro-Gutierrez
ASAli Hassan Shilleh
Ali Hassan Shilleh
WWWilliams Williams
Williams Williams
Holger Andreas RussHolger Andreas Russ
Holger Andreas Russ
Type 1 diabetes is a polygenic disease that results in an autoimmune response directed against insulin-producing beta cells. PTPN2 is a known high-risk type 1 diabetes associated gene expressed in both immune- and pancreatic beta cells, but how genes affect the development of autoimmune diabetes is largely unknown. We employed CRISPR/Cas9 technology to generate a functional knockout of PTPN2 in human pluripotent stem cells (hPSC) followed by differentiating stem-cell-derived beta-like cells (sBC) and detailed phenotypical analyses. The differentiation efficiency of PTPN2 knockout (PTPN2 KO) sBC is comparable to wild-type (WT) control sBC. Global transcriptomics and protein assays revealed the increased expression of HLA Class I molecules in PTPN2 KO sBC at a steady state and upon exposure to proinflammatory culture conditions, indicating a potential for the increased immune recognition of human beta cells upon differential PTPN2 expression. sBC co-culture with autoreactive preproinsulin-reactive T cell transductants confirmed increased immune stimulations by PTPN2 KO sBC compared to WT sBC. Taken together, our results suggest that the dysregulation of PTPN2 expression in human beta cell may prime autoimmune T cell reactivity and thereby contribute to the development of type 1 diabetes.

26 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RFRémi B. Fiancette
Rémi B. Fiancette
JHJunyue Huang
Junyue Huang
CSChristine Stephens
Christine Stephens
JHJessica E. Hibbert
Jessica E. Hibbert
GHGeorge Hewitt
George Hewitt
IAİlDem Akerman
İlDem Akerman
Human pluripotent stem cell-derived islets (SC-islets) offer an excellent medium for human pancreatic disease modelling and mechanistic studies into diabetes. While substantial progress has been made in differentiation protocols, their implementation in different laboratories result in variable β-cell proportions with contaminant non-endocrine and proliferative cell types. To date, no facility-level implementation exists for producing SC-islets that can be shipped and benchmarked across multiple sites. Here, we describe the scalable optimisation, standardization, and facility-level implementation of an established human stem cell differentiation strategy that consistently results in a high proportion of β-cells, with up to 75% of cells co-expressing C-peptide and the pancreatic endocrine marker, ISL1. Functionally, SC-islets exhibit glucose-responsive calcium influx and insulin secretion, recapitulating key physiological β-cell functions. Single-cell transcriptomic profiling reveals a simplified endocrine landscape dominated by β-cells, with a striking transcriptional similarity to human primary β-cells (Pearson’s r 2 ∼0.9). We observe smaller fractions of α- and enterochromaffin-like cells with very low levels of poly-hormonal or proliferating cell types (<3%). Taken together, we provide a well-defined, reproducible and accessible in vitro SC-islet platform benchmarked for functionality at multiple recipient sites.

2 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
RCRoberto Castro-Gutierrez
Roberto Castro-Gutierrez
ASAli Hassan Shilleh
Ali Hassan Shilleh
JBJessie Barra
Jessie Barra
WWWilliams Williams
Williams Williams
BNBalachandar Nedumaran
Balachandar Nedumaran
Holger Andreas RussHolger Andreas Russ
Holger Andreas Russ
Efficient and reproducible generation of functional stem cell-derived β cells (sBC) remains a major challenge for basic research and cell replacement therapy, partly due to incomplete understanding of endocrine induction during differentiation and challenges with clinical scale-up. Here, we dissect the individual contributions of commonly used endocrine differentiation factors on pancreatic progenitor maintenance, endocrine commitment, and hormone subset generation in a scalable 3D differentiation system. We demonstrated that starting pluripotent stem cell cluster size is a critical determinant for downstream sBC generation. We also verify that a commonly employed combination of endocrine induction molecules efficiently drives endocrine lineage commitment but yields limited β-cell generation. Detailed analysis of the effects of individual endocrine induction molecules revealed distinct effects: EGF or KGF preserved NKX6.1+ progenitors without induction of endocrine differentiation; Notch or BMP inhibition robustly induced endocrine marker expression but concurrently reduced NKX6.1 expression, resulting in predominant generation of glucagon-expressing cells; retinoic acid, thyroid hormone (T3), or TGFβ inhibition maintained high NKX6.1 levels while also promoting efficient insulin+ endocrine differentiation. These findings indicate NKX6.1 protein maintenance as a key determinant of human β-cell generation and show that endocrine differentiation factors exert divergent effects on lineage progression.

11 November 2026 in Developmental Cell
Verified
Journal Article
Closed access
ASAli Hassan Shilleh
Ali Hassan Shilleh
DHDavid Hodson
David Hodson